Hypoxic cancer ceils are found in all solid tumors and occur in regions where tumor growth outstrips new blood vessel formation. Hypoxic cancer cells are resistant to chemotherapy and radiation and are a major reason for the failure of cancer therapy. New knowledge of the cellular biology of the cell's response to hypoxia offers exciting new ways of attacking hypoxic cancer cells and exploiting their unique biology for selective therapy. The cells response to hypoxia is mediated by the HIF-1 transcription factor, a heterodimer composed of a hypoxia inducible HIF-.1 subunit and a constitutive HIF-1. subunit. Genes induced by HIF-1 allow the cancer cell to adapt its metabolism to the hostile anaerobic environment, to become resistant to programmed cell death (apoptosis) and to metastasize to new less hypoxic environments. HIF-1 also induces the production of a family of cytokines, including vascular endothelial growth factor (VEGF), that promote the formation of new tumor capillary blood vessels from pre-existing blood vessels (angiogenesis). We present evidence that a necessary factor for the hypoxia-induced increase in HIF-1 in cancer cells is the redox protein thioredoxin-1 (Trx-1). Trx-1 expression is increased in may human primary tumors where it is associated with aggressive tumor growth and decreased patient survival. We show that increased Trx-1 leads to increased hypoxia-induced HIF-.1 levels and HIF-1 transactivating activity, to increased expression of hypoxia induced genes such as VEGF and to increased tumor angiogenesis. The hypothesis upon which our work is based is that, acting by a redox mechanism, Trx-1 is necessary for the hypoxia-induced increase in HIF-.1 and its subsequent effects on tumor growth with increased angiogenesis. We also propose that drugs that inhibit the redox control of HIF.- will deprive the cancer cell of its hypoxic advantage and offer a novel and effective way of treating cancer. We have identified pleurotin as the first of a new class of HIF-.1 inhibitory antitumor agents that acts by inhibiting thioredoxin reductase, thus, reversing the redox effects of Trx-1 on HIF-.I. The objectives of our work are to conduct mechanistic studies of the redox regulation of HIF-.1 by Trx-1 and the inhibition of HIF-.1 by pleurotin.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA098920-01A1
Application #
6683375
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
2003-07-01
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$337,088
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Grandjean, Geoffrey; de Jong, Petrus R; James, Brian et al. (2016) Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1? Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. Cancer Res 76:4259-4269
Koh, Mei Yee; Gagea, Mihai; Sargis, Timothy et al. (2016) A new HIF-1?/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. Hepatology 63:1576-91
Koh, Mei Yee; Nguyen, Vuvi; Lemos Jr, Robert et al. (2015) Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer Res 75:316-29
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Spivak-Kroizman, Taly R; Hostetter, Galen; Posner, Richard et al. (2013) Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73:3235-47
Kim, Yon Hui; Liang, Han; Liu, Xiuping et al. (2012) AMPK? modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 72:2512-21
Koh, Mei Yee; Powis, Garth (2012) Passing the baton: the HIF switch. Trends Biochem Sci 37:364-72
Kim, Yon Hui; Coon, Amy; Baker, Amanda F et al. (2011) Antitumor agent PX-12 inhibits HIF-1? protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemother Pharmacol 68:405-13
Schwartz, David L; Bankson, James; Bidaut, Luc et al. (2011) HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol Cancer Res 9:259-70

Showing the most recent 10 out of 24 publications